The genomic drug developer has secured $15m in a pre-series B round led by Lilly Asia Ventures that included Huagai Capital, IDG Capital and WI Harper.
Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical firm Eli Lilly, has led a pre-series B round for China-based genomic medicine developer EdiGene sized at approximately $15m.
Private equity firm Huagai Capital, venture capital group IDG Capital and VC firm WI Harper Group also contributed to the round along with undisclosed insiders. EdiGene has not revealed details of its series A round but said it included IDG and WI Harper.
Founded in 2015, EdiGene is working on medical treatments…
